Skip to main content
. 2020 Mar 27;146(6):1451–1462. doi: 10.1007/s00432-020-03193-y

Table 4.

Diagnosis- and treatment-related factors associated with obstetric outcomes according to five different models: (1) type of diagnosis; (2) age at diagnosis; (3) CED score; (4) radiotherapy site; (5) stem cell transplantation

Total number of live births Preterm delivery SGA Caesarean section
N (%)a OR (95% CI) N (%)b OR (95% CI) N (%)c OR (95% CI)
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
Survivors 592 57 (9.8) 2.0 (1.2–3.5)d 59 (10.7) 1.1 (0.7–1.7)d 108 (19.2) 1.8 (1.2–2.6)d
Model 1: Type of diagnosisd
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
Leukaemia 191 13 (7.0) 1.4 (0.6–2.9) 16 (9.0) 0.8 (0.4–1.5) 35 (19.3) 1.8 (1.1–3.0)
Lymphoma 134 12 (9.2) 1.7 (0.7–3.7) 11 (8.7) 0.8 (0.4–1.7) 16 (12.6) 0.9 (0.5–1.9)
CNS tumours 25 4 (16.0) 4 (17.4) 6 (24.0) 2.2 (0.7–4.6)
Neuroblastoma and other peripheral nervous cell tumours 45 2 (4.4) 8 (19.0) 2.4 (1.1–5.3) 8 (18.6) 1.9 (0.8–4.6)
Renal tumours 53 10 (18.9) 4.9 (2.1–11.6) 3 (6.0) 12 (24.0) 2.7 (1.2–6.1)
Bone tumours 61 7 (11.9) 2.8 (1.1–7.0) 8 (14.0) 1.7 (0.7–4.0) 14 (24.1) 2.3 (1.1–5.1)
Soft tissue sarcoma 43 7 (16.3) 4.0 (1.3–12.6) 7 (17.5) 2.0 (0.7–5.8) 13 (31.7) 3.4 (1.4–8.4)
Germ cell tumours 21 1 (4.8) 1 (4.8) 2 (9.5)
Other 19 1 (5.3) 1 (5.3) 2 (10.5)
Model 2: Age at diagnosis (years)d
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
< 10 332 38 (11.7) 2.5 (1.4–4.4) 31 (10.0) 1.0 (0.6–1.6) 68 (21.4) 2.1 (1.4–3.2)
≥ 10 to< 13 105 9 (8.7) 1.9 (0.8–4.5) 12 (12.0) 1.2 (0.6–2.6) 15 (15.3) 1.4 (0.7–2.9)
≥ 13 155 10 (6.7) 1.3 (0.5–3.4) 16 (11.5) 1.2 (0.6–2.5) 25 (17.1) 1.4 (0.8–2.6)
Model 3: CED scoree
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
0 301 28 (9.6) 1.9 (1.0–3.6) 23 (8.3) 0.8 (0.5–1.4) 57 (19.5) 2.0 (1.2–3.1)
> 0 to ≤ 4000 mg/m2 78 6 (7.7) 1.1 (0.4–3.1) 11 (15.1) 1.5 (0.6–3.9) 15 (21.4) 2.1 (1.0–4.4)
> 4000 to ≤ 8000 mg/m2 82 12 (14.8) 3.0 (1.3–7.4) 9 (11.4) 1.2 (0.5–2.6) 24 (30.0) 2.9 (1.5–5.6)
> 8000 mg/m2 114 10 (8.8) 1.6 (0.7–3.6) 14 (13.0) 1.4 (0.7–2.8) 12 (11.5) 0.8 (0.4–1.8)
Model 4: Radiotherapy body sitef
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
No RT 305 28 (9.4) 2.1 (1.0–4.3) 19 (6.6) 0.5 (0.3–1.0) 45 (15.8) 1.6 (0.9–2.7)
Cranial/spinal RT 141 14 (10.1) 2.1 (1.0–4.5) 19 (15.0) 1.2 (0.6–2.3) 36 (26.1) 2.8 (1.5–5.0)
Lower abdominal/pelvic RT 54 8 (14.8) 4.0 (1.6–10.1) 4 (8.3) 11 (21.2) 2.1 (0.9–5.2)
TBI 2 1 (50.0) 1 (50.0) 0
Other RT 86 6 (7.2) 1.6 (0.6–4.6) 15 (18.8) 1.5 (0.6–3.7) 15 (18.3) 1.9 (0.9–4.2)
Model 5: Stem cell transplantation
Controls 651 31 (4.8) Ref. 61 (9.8) Ref. 77 (12.3) Ref.
No 577 56 (9.9) 2.1 (1.2–3.6) 57 (10.6) 1.1 (0.7–1.7) 106 (19.3) 1.8 (1.2–2.6)
Yes 6 0 0 1 (16.7)

Values represent the number (%) of women, unless indicated otherwise. The subcategories may not add up to the total number of women due to missing values

CED cyclophosphamide equivalent dose, CNS central nervous system, RT radiotherapy, SGA small for gestational age, TBI total body irradiation

aPercentage of the live births for whom the gestational week was known

bPercentage of the live births for whom SGA could be calculated

cPercentage of the live births for whom the method of delivery was known

dCorrected for age at time of pregnancy and educational level

eCorrected for age at time of pregnancy, educational level, and gonadotoxic radiotherapy (i.e. lower abdominal/pelvic RT and/or TBI) (yes or no)

fCorrected for age at time of pregnancy, educational level, and alkylating agent therapy (yes or no)